KBP will attend two scientific conferences this coming Spring to present our recent findings.
The first one is the NKF Spring Clinical Meetings on April 27th in Boston. A KBP team will have a poster presentation titled “Pharmacological Profile of KBP-5074, A Novel Non-Steroidal, Highly Selective, Mineralocorticoid Receptor Antagonist (MRA) For The Treatment of Cardiorenal Diseases”. KBP-5074 is currently in a Phase IIa study in CKD patients.
Then on June 16th, a KBP team will present 3 posters at the ASM Microbe 2016 conference. These posters focus on another lead compound, KBP-7072, a new generation of tetracycline with broad antibacterial efficacies. These posters will cover:
- Antibacterial Activity of KBP-7072 Against Clinical Isolates of Drug-Resistant Bacteria
- Effect of KBP-7072 on Bacterial Activity and Survival in a Klebseilla pneumoniae-induced Murine Pneumonia Model
- Effect of KBP-7072 on Bacterial Activity and Survival in a S. pneumoniae-induced Murine Pneumonia Model
Please look us up. We hope to see you there.